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Abstract
The fate of cells that disseminate from a primary breast tumour
remains poorly understood. Studies of the kinetics of recurrence in
breast cancer patients are raising important questions about the
biology of the metastatic process. Where do tumour cells reside
once they leave the primary tumour, and what factors influence
their dormancy and recurrent growth? Clinical data analyses are
leading to hypotheses about the biology of metastasis, dormancy
and recurrence. A combined clinical and experimental approach to
testing these hypotheses will help to clarify this important issue in
breast cancer biology and patient care.
Much remains to be learned about the biology of breast
cancer micrometastases, including their predeliction for late
clinical recurrences. When tumour cells have been dissemi-
nated systemically, where do they reside and what governs
their subsequent fate? In this issue of Breast Cancer
Research, Demicheli and colleagues [1] report on their
investigation into the kinetics of metastastases to distinct
metastatic sites, as well as the kinetics of contralateral breast
cancer and development of other primary tumours. The study
used data from 1,526 patients from the National Cancer
Institute of Milan, for whom data on the site of first recurrence
(bone, viscera, or soft tissue) were available. This study
reports that the kinetics of recurrence to different metastatic
sites followed the same bimodal pattern for recurrence (to
any site) described previously by these authors and others,
with a first peak at around 2 years and a second, smaller peak
at about 5 years [2-6]. In contrast, development of contra-
lateral breast cancer or other new cancers did not follow this
bimodal pattern, instead exhibiting a relatively constant, low
rate of occurrence over time, with no early peak [1]. These
findings suggest that the biology of metastasis development
is distinct from that of developing new contralateral breast or
other cancers. They also suggest that metastasis to different
sites follows the same kinetics of recurrence, perhaps
reflecting systemic biological similarities that affect meta-
stases, at least for the sites studied.
Concepts from experimental models of metastasis suggest
that cancer cells may be distributed from primary tumours via
the blood or lymphatic circulation, and arrested efficiently in
the first capillary bed encountered [7]. Once in new sites,
some cells may remain dormant but viable, resist cytotoxic
therapies and produce late-developing metastases [8,9].
Clinical support for these concepts comes from studies in
which carcinoma cells were identified in bone marrow of
cancer patients, and these cells appear to portend poor
outcome [10]. Although disseminated tumour cells have been
identified in bone marrow (because this tissue has been
examined), it is possible that they reside in many other organs
(which generally have not been examined), consistent with
experimental studies [8].
In an analysis of older literature, Weiss [11] concluded that
numbers of metastases detected at autopsy in a given organ
were usually (two-thirds of the time) in proportion to blood
flow to that organ from the site of the patient’s primary
tumour. In contrast, in the other third of tumour-secondary
site pairs there were more or fewer metastases than would
be expected based on blood flow alone [11]. (Interestingly,
among the latter were metastases from breast and prostate
cancer to bone, where more metastases were found at
autopsy than would be expected based on blood flow alone,
suggesting a favourable growth environment for these cells in
bone.) Additional autopsy studies looking for the presence of
disseminated micrometastases in multiple organs are needed.
It is unfortunate that the study by Demicheli and colleagues
[1] did not divide patients by hormone receptor status, and
this information was not available for this patient cohort.
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Saphner and colleagues [5] reported that patients with
oestrogen receptor (ER)-positive versus ER-negative tumours
have distinct recurrence kinetics, with ER-negative patients
exhibiting a greater hazard of recurrence during the first
5 years, and a lower hazard of recurrence from years 5 to 12,
as compared with ER-positive patients. This phenomenon
was well illustrated by the rates of recurrence in the National
Cancer Institute of Canada Clinical Trials Group MA17 trial
[12,13]. It would be most interesting to determine in more
recent patient series whether hormone receptor status is
associated with distinct patterns of recurrences to individual
metastatic sites.
The nature of the biology responsible for the bimodal peaks
has not yet been elucidated. Some experimental evidence
suggests that late-developing metastases, especially in the
era of adjuvant therapy, may represent emergence of cells
that had been in a dormant state at the time of administration
of adjuvant therapy [9]. Furthermore, the potential role played
by cancer stem cells in development of late metastases
remains to be determined [14]. The study by Demicheli and
coworkers [1] presents interesting and important concepts
that should be further assessed in other clinical series in
which data on sites of first recurrence are recorded, including
the effects of hormone receptor and human epidermal growth
factor receptor (HER)2 status as well as specific treatments.
A trial is currently underway that will assess the anti-HER2
therapy lapatinib in response to the chronic high and ongoing
relapse risk for this subtype of the disease [15]. In addition, it
would be interesting to include data on the kinetics of
metastases from breast cancer to brain, because these are
uncommon as a first site of metastasis (although metastasis
to brain is increasingly common in HER2-positive patients
treated with trastuzumab). These analyses will generate
hypotheses about the biology of metastasis and late-
developing metastases, which can be taken to further clinical
and experimental investigations to help identify the mecha-
nisms responsible.
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